此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项评估 iTind 与 UroLift 相比安全性的随机国际研究 (MT-08)

2026年9月25日 更新者:Olympus Corporation of the Americas

一项上市后、前瞻性、随机、对照、多中心国际研究,以评估临时植入镍钛合金装置 (iTind) 与 UroLift® 系统在有症状良性前列腺增生症 (BPH) 受试者中的安全性

The study objective is to evaluate the efficacy and safety of the iTind device compared to UroLift.

研究概览

详细说明

Both iTind and UroLift are minimally invasive treatment options for relieving lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). The iTind device is a temporary, self-expanding nitinol implant that remains in place for 5 to 7 days to reshape the prostatic urethra through localized ischemic pressure and tissue remodeling. In contrast, the UroLift system involves the permanent placement of transprostatic implants that retract the enlarged lateral lobes of the prostate to widen the urethral lumen.

This study is designed to directly compare the safety and effectiveness of the iTind device versus the UroLift system in treating LUTS due to BPH.

研究类型

介入性

注册 (估计的)

256

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Arizona
      • Phoenix、Arizona、美国、85054
        • 招聘中
        • Mayo Clinic Arizona
        • 首席研究员:
          • Mitchell Humphreys, MD
        • 接触:
      • Tucson、Arizona、美国、85704
        • 终止
        • Arizona Urology Specialists
    • California
      • Fresno、California、美国、93720
        • 招聘中
        • Urology Associates of Central California
        • 首席研究员:
          • William Schiff, MD
        • 接触:
      • Sacramento、California、美国、95823
        • 招聘中
        • Golden State Urology
        • 首席研究员:
          • Prithipal Sethi, MD
        • 接触:
    • Illinois
      • Evanston、Illinois、美国、60201
        • 终止
        • NorthShore University Health System Research Institute
    • Louisiana
      • New Orleans、Louisiana、美国、70119
        • 主动,不招人
        • Southeast Louisiana Veterans Health Care System
    • Minnesota
      • Woodbury、Minnesota、美国、55125
        • 撤销
        • Minnesota Urology
    • Nebraska
      • Omaha、Nebraska、美国、68124
        • 招聘中
        • The Urology Center
        • 首席研究员:
          • Sida Niu, MD
        • 接触:
    • Nevada
      • Las Vegas、Nevada、美国、89121
    • New York
      • Syosset、New York、美国、11791
        • 招聘中
        • Feinstein Institutes for Medical Research / Northwell Health
        • 首席研究员:
          • Bilal Chughtai, MD
        • 接触:
    • Tennessee
      • Germantown、Tennessee、美国、38138
        • 招聘中
        • The Conrad Pearson Clinic
        • 首席研究员:
          • Adam Stewart, MD
        • 接触:
    • Texas
      • Austin、Texas、美国、78705
        • 招聘中
        • Midtown Urology Associates
        • 首席研究员:
          • Tyler McClintock, MD
        • 接触:
      • Houston、Texas、美国、77027
        • 招聘中
        • Houston Metro Urology
        • 接触:
        • 首席研究员:
          • Mark Sutton, MD
      • San Antonio、Texas、美国、78240
        • 招聘中
        • The Urology Place
        • 首席研究员:
          • Naveen Kella, MD
        • 接触:
    • Virginia
      • Alexandria、Virginia、美国、22311
        • 招聘中
        • Potomac Urology Center
        • 首席研究员:
          • Nilay Gandhi, MD
        • 接触:
      • Dunfermline、英国、KY12 0SU
        • 招聘中
        • Queen Margaret Hospital
        • 首席研究员:
          • Feras Al Jaafari, MD
        • 接触:
      • London、英国、GU16 7UJ
        • 招聘中
        • Frimley Park Hospital
        • 首席研究员:
          • Neil Barber, MD
        • 接触:
      • Norwich、英国、NR4 7UY
        • 招聘中
        • Norfolk & Norwich University Hospital
        • 首席研究员:
          • Mark Rochester, MD
        • 接触:
    • Middlesex
      • Isleworth、Middlesex、英国、TW7 6AF
        • 招聘中
        • Chelsea and Westminster Hospital
        • 首席研究员:
          • Samuel Bishara, MD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

描述

Inclusion Criteria:

  1. Diagnosis of lower urinary tract symptoms presumed to be secondary to benign prostatic enlargement causing bladder outlet obstruction for which treatment is recommended
  2. Willing and able to provide informed consent
  3. Males ≥ 50 years of age or older
  4. PSA < 4 ng/ml or if the PSA is 4 - 10 ng/ml, prostate cancer must be ruled out to the satisfaction of the Principal Investigator (PI) by local standard of care methods within prior 6 months
  5. Prostate volume up to 75 cc (inclusive) documented by cross-sectional imaging (TRUS, MRI, etc.). Results from standard of care imaging may be accepted up to 6 months prior to Screening
  6. International Prostate Symptom Score (IPSS) for urinary symptoms ≥ 13
  7. Maximum urinary flow rate (Qmax) of ≤ 15 mL/sec and ≥ 5 mL/sec (voided volume must be ≥ 125 mL)
  8. Willing and able to complete all study visits including questionnaires at baseline and at follow-up visits

Exclusion Criteria:

  1. History of prostate cancer or suspected, should be ruled out to the satisfaction of the PI by local standard of care methods within prior 6 months
  2. Confirmed bladder cancer within the last 2 years or currently suspected bladder cancer
  3. History of acute bacterial prostatitis within the last 2 years
  4. Median lobe obstruction of the prostate as confirmed by cross-sectional imaging
  5. PSA value > 10 ng/ml
  6. Contraindicated for iTind or UroLift as determined by the PI
  7. Neurogenic bladder and/or sphincter abnormalities due to Parkinson's disease, multiple sclerosis, cerebral vascular accident, diabetes or other neurological disorders that affect bladder function
  8. Clinically significant bladder diverticulum
  9. Diagnosed with urethral stricture, meatal stenosis, bladder neck contracture, rectal disease, artificial urinary sphincter, incompetent sphincter, urinary incontinence due to incompetent sphincter
  10. Prior rectal surgery (other than hemorrhoidectomy) or history of rectal disease treatment if the therapy may potentially cause injury to site (e.g., if a transrectal probe is used), pelvic radiotherapy or radical pelvic surgery, urinary diversion surgery, prostate surgery, balloon dilation, urethral stent implantation, laser prostatectomy, or any other invasive treatment to the prostate, or penile prosthesis if it may prevent insertion of the iTind or UroLift device
  11. An active urinary tract infection during randomization
  12. Clinically significant hematuria within the last 3 months or ongoing cystolithiasis
  13. Prostate volume > 75 cc
  14. Post-void residual volume (PVR) > 250 mL
  15. Actively using catheterization or unable to void naturally
  16. Unable to complete a 2-week washout period for alpha blockers prior to procedure or unable to discontinue 5ARIs or daily use of PDE5 inhibitors by the time of procedure
  17. Taking anti-platelet or anticoagulants (except low dose aspirin - 81 mg - 100 mg) within the last 7 days prior to procedure
  18. Known or suspected allergy to nickel, titanium or polyester/polypropylene

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:iTind arm

The iTind is a minimally invasive temporary implant

The iTind is implemented for 5-7 days

有源比较器:UroLift

The UroLift is a minimally invasive permanent implant

UroLift is a minimally invasive procedure where permanent implants are placed in the prostate.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Difference in change of IPSS from baseline between iTind and UroLift groups at 3 months
大体时间:3 months

Difference in change of IPSS from baseline between iTind and UroLift groups at 3 months

3 months

次要结果测量

结果测量
措施说明
大体时间
Difference in change of IPSS from baseline between iTind and UroLift groups at 12 months
大体时间:12 month

Difference in change of IPSS from baseline between iTind and UroLift groups at 12 months

12 month
Incidence of all intraoperative and post-operative adverse events (AEs) (i.e., related to procedure and/or device) through 3 months post-procedure.
大体时间:3 month

Incidence of all intraoperative and post-operative adverse events (AEs) (i.e., related to procedure and/or device) through 3 months post-procedure.

3 month
Difference in change of IPSS from baseline between iTind and UroLift groups at 1, 6, 24, and 36 months
大体时间:1, 6, 24, and 36 months

Difference in change of IPSS from baseline between iTind and UroLift groups at 1, 6, 24, and 36 months

1, 6, 24, and 36 months
Difference in change of QoL scores (SHIM, MSHQ-EjD, SF-6D) from baseline between iTind and UroLift at 1, 3, 6, 12, 24, and 36 months
大体时间:1, 3, 6, 12, 24, and 36 months

Difference in change of QoL scores (SHIM, MSHQ-EjD, SF-6D) from baseline between iTind and UroLift at 1, 3, 6, 12, 24, and 36 months

1, 3, 6, 12, 24, and 36 months
Difference in rate of re-intervention between iTind and UroLift groups at 1, 3, 6, 12, 18, 24, and 36 months
大体时间:1, 3, 6, 12, 18, 24, and 36 months

Difference in rate of re-intervention between iTind and UroLift groups at 1, 3, 6, 12, 18, 24, and 36 months

1, 3, 6, 12, 18, 24, and 36 months
Difference in reporting between iTind and UroLift groups at 1, 6, 12, 18, 24, and 36, months •Overall incidence of procedure and/or device related adverse events
大体时间:1, 6, 12, 18, 24, and 36, months

Difference in reporting between iTind and UroLift groups at 1, 6, 12, 18, 24, and 36, months

•Overall incidence of procedure and/or device related adverse events

1, 6, 12, 18, 24, and 36, months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Neil Barber, MD、Frimley Park Hospital
  • 首席研究员:Bilal Chughtai, MD、Northwell Health

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年9月26日

初级完成 (估计的)

2027年7月15日

研究完成 (估计的)

2030年5月31日

研究注册日期

首次提交

2021年2月7日

首先提交符合 QC 标准的

2021年2月14日

首次发布 (实际的)

2021年2月17日

研究记录更新

最后更新发布 (实际的)

2026年9月29日

上次提交的符合 QC 标准的更新

2026年9月25日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅